Ireland currently obtains its avian and bovine tuberculin purified protein derivatives (PPDs) from a 14 single source. Because problems of supply or quality cannot be discounted, it is prudent that Ireland 15 identify alternative supplier(s) as part of a broad risk management strategy. Therefore, the aim of this 16 study was to compare the performance of a number of different tuberculin combinations (that is, 17 pairings of bovine and avian PPD; with different manufacturers) in the single intradermal comparative 18 tuberculin test (SICTT), as currently performed in Ireland. The study was randomised, controlled and 19 double-blinded. A total of 2,172 cattle were used in the study. Each animal was tested using two 20 SICTTs, the first based on the tuberculin combination in current use, and the second using one of six 21 trial tuberculin combinations. Analyses were conducted to compare both reactor-status and skin 22 increase. For each control/trial tuberculin combination, there was good agreement between the control 23 and trial reactor-status. Differences in skin increases were mainly confined to animals categorised as 24 either negative or severe inconclusive. However, the measured differences were minor, and unlikely to 25 have a significant impact on the actual test outcome, either for individual animals or for herds. In 26 conclusion, while further studies determining sensitivity and specificity in Ireland would have to be 27 done in the event of a change in tuberculin PPD there should be minimal disruption of the national 28 Page 2 of 26 A c c e p t e d M a n u s c r i p t 2 programme if alternative tuberculin PPDs meeting WHO, OIE and EU regulations were used. In this 29 study, the precision of the guinea pig bio-assay to assess tuberculin potency was low and therefore 30 Ireland should maintain its practice of periodically assessing potency in naturally infected cattle, even 31 though this is not currently required under WHO, OIE or EU Regulations. 32 33 34 intradermal comparative tuberculin test 35 36 M a n u s c r i p t 26 a. The reactor-status is based on the results from the control SICTT b. Standard reactors, standard and severe inconclusive reactors c. The difference in skin measurement (in mm; if positive, trial is larger) at the trial and control bovine sites d. The significance of the measurement differences was tested using a Wilcoxon signed-rank test.(* p ≤ 0.05;** p ≤ 0.01) e. The difference in skin measurement (in mm; if positive, trial is larger) at the trial and control avian sites f. The difference (in mm; if positive, trial is larger) between the trial and control bovine-avian differential
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Introduction

38
The single intradermal comparative tuberculin test (SICTT) to detect tuberculosis (TB) in cattle is in 39 routine use as part of the bovine TB eradication programme in Ireland (Good et al., 2007) . This test is 40 conducted by comparing the separate immunological cell-mediated response in each animal to avian 41 and bovine tuberculin purified protein derivative (PPD) (Monaghan et al., 1994) , used in accordance 42 with the protocols laid down in Directive 64/432/EEC (European Commission, 1964) . When one or 43 more animals in a herd show a positive response to the test, herd-level statutory controls are applied.
45
In Ireland, ID-Lelystad BV (Institute for Animal Science & Health, Lelystad, The Netherlands) 46 currently supplies all of the avian and bovine tuberculin PPD used in the programme. Because problems of supply or quality cannot be discounted, it is prudent that Ireland identify alternative 48 supplier(s) as part of a broad risk management strategy. There are a number of national TB eradication 49 programmes in the Europe Union (Caffrey, 1994; Reviriego Gordejo and Vermeersch, 2006) . As yet, 50 however, no work has been reported on the impact of SICTT performance, using tuberculin PPD from 51 different suppliers on these programmes. Therefore, the aim of this study was to compare the 52 performance of a number of different tuberculin combinations (that is, pairings of bovine and avian 53 PPD; with comparable potency and similar avian/bovine potency differentials but with different 54 manufacturers) in the SICTT as currently performed in Ireland. 
123
Each tuberculin in each combination was sourced from a single production batch. The potency of each 124 avian and bovine tuberculin was assessed in TB-sensitised guinea pigs in accordance with annex B to 125 Directive 64/432/EEC, as amended (European Commission, 1964) , both by each manufacturer during 126 production, and also by ID Lelystad, as blinded samples prior to the start of the study. The potency of 127 the bovine tuberculin was also assessed in naturally infected tuberculous cattle, as described 128 previously (Haagsma, 1997) , by one of the manufacturers during production, and for each bovine 129 tuberculin at the Central Veterinary Research Laboratory, Ireland, prior to the start of the study (Table   130 1).
132
A single veterinary practitioner conducted the field aspects of the trial. Prior to the trial, the tuberculin 133 in each combination was decanted into sterile vials of uniform size and shape, then coded using one of 134 two letters (for example, the combination from manufacturer A was coded using either F or M; Table   135 1). The administering veterinarian was blinded to the identity of the trial tuberculin combinations, and 136 also to the fact that the control and one trial tuberculin combination were identical. The results from each trial and control test were compared, using methods suitable for paired data.
163
Animals were assigned a trial and a control reactor-status, according to the definitions given earlier, 164 and these data were compared using Cohen's kappa (Dohoo et al., 2003) . In addition, we used For each animal, we recorded the skin increases (in mm) at each bovine and avian site (trial bovine, 171 trial avian, control bovine, control avian). We then calculated the difference between the two paired 172 measurements (for each animal, a trial and a control bovine-avian [B-A] differential). A positive B-A 173 differential indicated that the bovine measurement was greater than the avian measurement. For each 174 animal, we also calculated the difference between the trial and control bovine measurements (bovine 175 difference), the trial and control avian measurements (avian difference), and the trial and control 176 B-A differentials (B-A differential difference). Each of these results was positive if the trial 177 measurement was larger than the control measurement. Each animal was then allocated to a reactor- In some animals there were discrepancies in the classification of reactor-status, based on results from 199 the trial and control tests ( 
219
Wallis test: p = 0.106) or avian (p = 0.202) difference, nor in the bovine-avian differential difference 220 (p = 0.532).
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Among animals with non-negative results, there was a significant difference between the bovine and 223 avian difference in each trial/control combination, except G/control (bovine difference: p = 0.536; 224 avian difference: p = 0.829). These differences mainly relate to animals classified as severe 225 inconclusives. There was no significant differences in the B-A differential ( 235 Therefore, the effect of different tuberculin PPD combinations on reactor-status is of particular 236 importance. For each control/trial tuberculin combination, we found good agreement between the 237 control and trial reactor-status in this study (Table 3) . Further, the level and pattern of agreement 238 between the control and trial combinations G and L (each using the tuberculin PPD combination 239 currently in use in Ireland) was similar to that observed with each other control/trial combinations. The 240 level of agreement was also similar (kappa: 0.49 to 0.77), and differences almost invariably non-241 significant, when each category of reactor-status was considered separately (Table 4) . Note, however, 242 that the number of animals in some categories may have been too small to detect any difference, if 243 present. Only a limited number of reactors were identified in the study, which reflects the very low 244 animal-level incidence of tuberculosis in Ireland (More and Good, 2006; ~0.4% annually). We could 245 have identified a greater number of reactor animals, but at considerable cost in time and materials.
247
The study also provided insights into the effect of different tuberculin combinations on skin reactivity 248 to the avian and bovine tuberculin PPD. Among all non-negative animals (standard reactors, standard 249 inconclusives, severe inconclusives), there were no significant differences between the control and Page 10 of 26 A c c e p t e d M a n u s c r i p t 10 each trial combination in the B-A differential difference (Table 5 ). The B-A differential (that is, the 251 bovine skin increase minus the avian skin increase) is used to categorise animals into a reactor-status.
252
Therefore, we are confident that similar field results will have been achieved, with each of the 253 tuberculin combinations under investigation. Based on the detailed information presented in Table 5,   254 we can identify some subtle differences in the performance of the different tuberculin combinations.
255
With each of the control/trial combinations, there were significant differences in both the bovine and 256 avian difference (that is, the difference between the trial and control skin increases at the bovine and 257 avian sites, respectively). In most cases, the control (as compared to trial) skin increase was greater, at 258 both the avian and bovine sites. We believe that these differences are the result of site effects, noting 259 that the control and trial tests were conducted at sites on the anterior and posterior neck, respectively.
260
Although it would have been preferable to use equivalent sites on each side of the neck, this was not 261 possible due to concerns relating to access and operator health and safety. Latin-square designs are 262 used in the cattle bio-assays specifically because sensitivity is known to be greater at the anterior 263 compared with the posterior cervical area (E. Costello, pers. comm.). In a practical sense, this study 264 has shown that it is the relative -rather than the absolute -location of the avian and bovine sites that 265 is of greatest importance. Although a location at the border of the middle and anterior third of the neck 266 is recommended (European Commission, 1964) , the A-B difference will not significantly alter if sites 267 anterior or posterior to this are chosen. However, to ensure equivalent skin sensitivity at both the avian 268 and bovine sites, it is important that these sites are both located on a line that is parallel to the angle of 269 the shoulder.
271
The observed differences in skin reactivity to the avian and bovine tuberculin PPD at the control and 272 trial sites were mainly confined to animals categorised as either negative or severe inconclusive (Table   273   5 ). However, the measured differences were minor, and as such unlikely to have a significant impact 274 on the actual test outcome, either for individual animals or for herds. In Ireland, herd control would 275 only be initiated following the detection of at least one standard reactor or an animal that had tested 276 standard inconclusive on two consecutive occasions. Some of these discrepancies may have occurred 
288
A number of steps were taken during this study to minimise a range of potential biases. The study was 289 conducted in a commercial fattening unit where cattle of mixed age, breed and sex from throughout 290 Ireland are assembled. These animals will each have been tested using the SICTT at some point during 291 the 12 months preceding their entry into the unit, and it was anticipated that at least some would have 292 been exposed under natural field conditions to M. bovis infection prior to acquisition by the enterprise.
293
For logistic reasons, the study animals were selected using convenience sampling; essentially whole 294 batches of cattle shortly before slaughter. We have no reason to believe that the study animals are not 
312
Any temporal effect of skin reactivity is believed to be related to a seasonal risk in exposure rather 313 than seasonal changes in immune response (Martin et al., 2001) .
315
In this study, the potency estimates from the guinea pig bio-assay were imprecise. Assay repeatability 316 is in part due to the inherent variability of tuberculin PPD. Bovine tuberculin PPD has been described 317 as a poorly defined, complex mixture containing more than 100 individual components in various 318 stages of denaturation (Pollock et al., 2001) , and is known to vary widely both in protein content and 319 antigenic profile (Tameni et al., 1998) . This may explain, at least in part, the variation in estimates of 320 the potency of the ID Lelystad bovine tuberculin PPD that were obtained in this facility during 321 production and in association with the trial (Table 1) and not more then 200% of the estimated potency, and the estimated potency not less than 75% and 331 not more than 133%, and not less than 66% and not more than 150%, of the stated potency of 20,000
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